# Synerkine Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synerkine-pharma-b-v

- Industry: Pharmaceuticals
- Headquarters: Leiden, Netherlands
- Website: www.synerkinepharma.com
- Total disclosed funding: $20M
- Latest round: Series A (Oct 12, 2023)
- Investors on record: 5

## About

Synerkine Pharma B.V. is a biotechnology company specializing in innovative non-opioid pain treatments, leveraging proprietary technology focused on interleukin 10 (IL-10) to develop therapeutics for chronic pain conditions.Founded in 2018 and headquartered in Leiden, Netherlands, Synerkine Pharma B.V. focuses on creating new therapeutic solutions for pain management. In October 2023, the company secured EUR 12.1 million in Series A funding, led by Flerie Invest, to further its development initiatives. The CEO, Hans Preusting, has a track record of leading ventures within this sector.Synerkine Pharma specializes in the development of innovative non-opioid pain solutions, particularly utilizing interleukin 10 (IL-10) based therapeutics aimed at conditions such as Complex Regional Pain Syndrome. These therapeutics have received European Orphan Drug Designation and are marketed in Europe, with plans for further international expansion.The company utilizes a business model that involves strategic partnerships with healthcare institutions and may include direct-to-consumer channels for its products. With a focus on its flagship IL-10 based therapeutics, revenue is anticipated to be driven by licensing agreements and sales to healthcare providers, reflecting the industry's growing demand for non-opioid alternatives.Following the recent Series A funding round on October 12, 2023, where Synerkine Pharma B.V. raised EUR 12.1 million, the company aims to expedite the clinical development of its cytokine fusion protein. Plans include introducing new products targeting various pain conditions and expanding into additional international markets to enhance its product availability and reach.

## Funding rounds

- Series A, Oct 12, 2023, $13M — Thuja Capital, InnovationQuarter, Flerie Invest, Utrecht Holdings
- Series A, Dec 16, 2021, $4M — Thuja Capital, Utrecht Holding BV, Flerie Invest
- Series A, Mar 25, 2019, $3.7M — Thuja Capital

## Investors

- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A
- Utrecht Holding BV — Series A
- Flerie Invest (https://capitalatlas.ai/funds/flerie-invest) — Series A
- InnovationQuarter (https://capitalatlas.ai/funds/innovationquarter) — Series A
- Utrecht Holdings (https://capitalatlas.ai/funds/utrecht-holdings) — Series A